RxDoctor Payments Data

Marion Studebaker, MD

Family Medicine · Yukon, OKNPI 1306875729

Payments from drug & device makers

$12,981in general payments, 2019–2025

Across 932 payments — averaging $13.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • Boehringer Ingelheim$1K
  • AstraZeneca$1K
  • AbbVie$977
  • plus $6K from 38 others

What the payments were for

  • Food & beverage$12,80399%
  • Education$1781%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,981 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$156,069
Medicare patients
381
Services billed
3,157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$89,125
JardianceEmpagliflozin73$64,045
EliquisApixaban69$61,892
TrulicityDulaglutide36$52,652
JanuviaSitagliptin Phosphate34$45,089
FarxigaDapagliflozin Propanediol29$41,607
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$33,786
MyrbetriqMirabegron44$23,689
RybelsusSemaglutide15$22,857
MounjaroTirzepatide16$19,378
Breo ElliptaFluticasone/Vilanterol21$9,984
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$9,388
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,328
Levothyroxine Sodium614$5,975
PremarinEstrogens, Conjugated14$5,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,269$111,98283 claims
Lilly USA, LLCTrulicity, Mounjaro$1,286$72,03052 claims
PfizerEliquis, Premarin$1,414$67,45083 claims
Boehringer IngelheimJardiance$1,114$64,04573 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$813$53,15875 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,053$53,07056 claims
MerckJanuvia, Belsomra$397$49,78247 claims
Astellas Pharma US IncMyrbetriq$847$23,68944 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Yukon

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →